Why is ERIS Lifescience falling/rising?

As of 26-Jun, ERIS Lifesciences Ltd is experiencing a decline in its stock price, currently at 1,622.50, reflecting a decrease of 3.3 or 0.2%. The stock has underperformed its sector today by 0.28%, and its delivery volume has significantly dropped by 69.77% compared to the 5-day average, indicating falling investor participation. Despite a strong performance over the past year with a return of 55.74%, the stock has shown a negative trend in the short term, with a 6.15% decline over the past week. While the company boasts high management efficiency and strong debt servicing capabilities, concerns about poor long-term growth and a high valuation relative to its earnings may be contributing to the recent price decline.
In the broader market context, the Sensex has increased by 2.94% over the past week, contrasting with ERIS Lifesciences' negative performance. Although the stock has outperformed the benchmark over longer periods, such as 18.53% year-to-date and 147.35% over three years, the recent underperformance in the short term suggests that investors may be reacting to the company's declining profit margins and high valuation metrics. This divergence from the benchmark performance could be influencing investor sentiment negatively, leading to the stock's current downward movement.